• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

    2/9/24 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email

    CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

    Palatin Technologies, Inc.

    Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

    Schedule for the Operating Results Press Release, Conference Call / Audio Webcast



    Q2 Fiscal Year 2024 Results Press Release

    2/15/2024 at 7:30 a.m.ET





    Q2 Fiscal Year 2024 Conference Call-Live

    US Toll Free Dial-In Number:

    International Dial-In Number:

    Participant Access Code:

    2/15/2024 at 11:00 a.m. ET

    1-888-506-0062

    1-973-528-0011

    397299





    Q2 Fiscal Year 2024 Conference Call-Replay 

    US Toll Free Dial-In Number: 

    International Dial-In Number:

    Participant Access Code: 

    2/15/2024-2/29/2024

    1-877-481-4010

    1-919-882-2331

    49945

    The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.

    About Palatin 

    Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-second-quarter-fiscal-year-2024-results-teleconference-and-webcast-to-be-held-on-february-15-2024-302058387.html

    SOURCE Palatin Technologies, Inc.

    Get the next $PTN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    SEC Filings

    View All

    SEC Form 10-Q filed by Palatin Technologies Inc.

    10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/14/25 5:00:30 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by Palatin Technologies Inc.

    424B4 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/8/25 5:27:16 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/8/25 5:26:19 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    4/11/24 4:45:17 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T sold $8,274 worth of shares (4,999 units at $1.66), decreasing direct ownership by 2% to 235,456 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    8/2/24 5:01:24 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 16,171 shares, decreasing direct ownership by 6% to 240,455 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    7/31/24 4:31:03 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palatin Announces 1-for-50 Reverse Stock Split

    PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB:PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. The Reverse Stock Split will become effective on August 8, 2025, at 5:00 p.m., Eastern Daylight Time (the "Effective Time") and the Common Stock is expected to begin trading on OCTQB Market of the OTC Markets on a Reverse Stock Split-adjusted basis on August 11, 2025 at market open. The Company's ticker symbol on the OTCQB will be PTNTD for 20 trading days, including the effective date. One of

    8/8/25 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

    Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM ESTCRANBURY, N.J., May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2025. "We had a strong quarter operationally, with significant progress across both our obesity and ocular pipelines," said Carl Spana, Ph.D., Pre

    5/14/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

    Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and functionTopical and systemic administration options enable potential for earlier intervention than current therapiesResults support the continued development of PL9654 and PL9655 for the treatment of diabetic retinopathy (DR)CRANBURY, N.J., May 9, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new

    5/9/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Palatin Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously

    11/24/21 6:07:03 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Palatin Technologies Inc. (Amendment)

    SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/24 2:55:16 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palatin Technologies Inc.

    SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/23 1:19:39 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Financials

    Live finance-specific insights

    View All

    Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

    Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

    2/13/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

    CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

    2/10/25 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

    Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a

    11/14/24 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care